Andrew B Lassman
Overview
Explore the profile of Andrew B Lassman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
6708
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Ellingson B, Sanvito F, Pope W, Cloughesy T, Huang R, Villanueva-Meyer J, et al.
AJNR Am J Neuroradiol
. 2024 Dec;
46(1):221-222.
PMID: 39730160
No abstract available.
3.
Ellingson B, Sanvito F, Cloughesy T, Huang R, Villanueva-Meyer J, Pope W, et al.
AJNR Am J Neuroradiol
. 2024 Jun;
45(12):1846-1856.
PMID: 38926092
Radiographic assessment plays a crucial role in the management of patients with central nervous system (CNS) tumors, aiding in treatment planning and evaluation of therapeutic efficacy by quantifying response. Recently,...
4.
Wen P, van den Bent M, Youssef G, Cloughesy T, Ellingson B, Weller M, et al.
J Clin Oncol
. 2023 Sep;
41(33):5187-5199.
PMID: 37774317
Purpose: The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some...
5.
Vize C, Kim S, Matthews T, Macsai M, Merrell R, Hsu S, et al.
Ophthalmic Res
. 2023 May;
66(1):1030-1043.
PMID: 37257422
Introduction: The Understanding New Interventions with GBM ThErapy (UNITE) study was designed to assess the effect of prophylaxis for ocular side effects (OSEs) in patients with glioblastoma receiving the antibody-drug...
6.
Al-Dalahmah O, Argenziano M, Kannan A, Mahajan A, Furnari J, Paryani F, et al.
Nat Commun
. 2023 May;
14(1):2586.
PMID: 37142563
Glioblastoma (GBM) diffusely infiltrates the brain and intermingles with non-neoplastic brain cells, including astrocytes, neurons and microglia/myeloid cells. This complex mixture of cell types forms the biological context for therapeutic...
7.
Mair M, Bartsch R, Le Rhun E, Berghoff A, Brastianos P, Cortes J, et al.
Nat Rev Clin Oncol
. 2023 Apr;
20(6):372-389.
PMID: 37085569
Antibody-drug conjugates (ADCs), a class of targeted cancer therapeutics combining monoclonal antibodies with a cytotoxic payload via a chemical linker, have already been approved for the treatment of several cancer...
8.
Mundi P, Dela Cruz F, Grunn A, Diolaiti D, Mauguen A, Rainey A, et al.
Cancer Discov
. 2023 Apr;
13(6):1386-1407.
PMID: 37061969
Significance: Complementary precision cancer medicine paradigms are needed to broaden the clinical benefit realized through genetic profiling and immunotherapy. In this first-in-class application, we introduce two transcriptome-based tumor-agnostic systems biology...
9.
Carneiro B, Papadopoulos K, Strickler J, Lassman A, Waqar S, Chae Y, et al.
Neurooncol Adv
. 2023 Feb;
5(1):vdac183.
PMID: 36814898
Background: Serclutamab talirine (Ser-T, formerly ABBV-321) is an antibody-drug conjugate consisting of an antibody (AM-1-ABT-806) directed against activated epidermal growth factor receptor (EGFR) and a pyrrolobenzodiazepine dimer. We investigated Ser-T...
10.
Lassman A, van den Bent M
Neuro Oncol
. 2023 Feb;
25(6):1015-1016.
PMID: 36789896
No abstract available.